US Oncology Reports First Quarter 20...(d) ...),Health

Three Months Ended Three Months Ended

March 31, December 31,

2008 2007 2007

Adjusted EBITDA (1) $52,112 $57,217 $58,034

Changes in assets and liabilities 36,831 (835) 45,954

Deferred income tax provision (10,040) (2,236) (699)

Interest expense, net (36,279) (31,025) (36,913)

Income tax benefit 8,256 609 7,869

Net cash provided by operating

activities $50,880 $23,730 $74,245

(1) US Oncology Holdings incurs certain general and administrative costs

that are incremental to the amounts incurred by US Oncology. During

the quarters ended March 31, 2008 and 2007 and the quarter ended

December 31, 2007, these expenses were $51 thousand, $41 thousand

and $(21) thousand, respectively, of general and administrative

costs, and are not included in the determination of US Oncology

Adjusted EBITDA of $52.1 million, $57.2 million and $58.0 million,

respectively, for these periods.

US ONCOLOGY HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands)

(unaudited)

Three Months Ended

March 31,

2008 2007

Cash flows from operating activities:

Net cash provided by operating activities $50,880 $23,730

Cash flows from investing activities:

Proceeds from sale of property and equipment
'/>"/>